- Home
- VANI vs IKNA Comparison
VANI vs IKNA Comparison
Compare VANI & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- IKNA
- Stock Information
- Founded
- VANI 1998
- IKNA 2016
- Country
- VANI United States
- IKNA United States
- Employees
- VANI N/A
- IKNA N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- IKNA Health Care
- Exchange
- VANI Nasdaq
- IKNA Nasdaq
- Market Cap
- VANI 69.3M
- IKNA 81.6M
- IPO Year
- VANI 2014
- IKNA 2021
- Fundamental
- Price
- VANI $1.15
- IKNA $1.39
- Analyst Decision
- VANI Strong Buy
- IKNA Buy
- Analyst Count
- VANI 1
- IKNA 2
- Target Price
- VANI $3.00
- IKNA $3.00
- AVG Volume (30 Days)
- VANI 83.2K
- IKNA 167.1K
- Earning Date
- VANI 03-25-2025
- IKNA 03-11-2025
- Dividend Yield
- VANI N/A
- IKNA N/A
- EPS Growth
- VANI N/A
- IKNA N/A
- EPS
- VANI N/A
- IKNA N/A
- Revenue
- VANI N/A
- IKNA $659,000.00
- Revenue This Year
- VANI N/A
- IKNA N/A
- Revenue Next Year
- VANI N/A
- IKNA N/A
- P/E Ratio
- VANI N/A
- IKNA N/A
- Revenue Growth
- VANI N/A
- IKNA N/A
- 52 Week Low
- VANI $1.01
- IKNA $1.22
- 52 Week High
- VANI $7.80
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- VANI 43.02
- IKNA 43.10
- Support Level
- VANI $1.12
- IKNA $1.40
- Resistance Level
- VANI $1.19
- IKNA $1.53
- Average True Range (ATR)
- VANI 0.03
- IKNA 0.06
- MACD
- VANI 0.00
- IKNA 0.00
- Stochastic Oscillator
- VANI 42.86
- IKNA 28.57
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.